We start the new year with an article by Lebrec et al., 2021 covering CAR-T / TCR immunotherapy research findings with a focus on nonclinical safety evaluation.
Engineered T cell therapies provide huge opportunities to address current unmet medical needs but present also unique challenges in terms of safety assessment during nonclinical and clinical development.
Read the article to find out about the unique challenges of nonclinical safety evaluation of engineered T-cell therapies, such as cytokine release syndrome, neurotoxicity, on-target/off-tumor toxicities, off-target effects, gene editing or vector integration-associated genomic injury.
Find the article here
